FATE THERAPEUTICS, INC. (NASDAQ:FATE) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
| 99.2 | Press release, dated September 11, 2019. |
FATE THERAPEUTICS, INC. (NASDAQ:FATE) Files An 8-K Entry into a Material Definitive Agreement
FATE THERAPEUTICS INC Exhibit
EX-1.1 2 d800399dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 EXECUTION VERSON 8,…
To view the full exhibit click here
About FATE THERAPEUTICS, INC. (NASDAQ:FATE)
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
